Clinical trialNCT05783609RecruitingPhase 2Interventional

Epcoritamab and Rituximab for First-line Follicular Lymphoma

SponsorReid Merryman, MDEnrollment100Follicular LymphomaLow Grade Non-Hodgkin's Lymphoma, Adult

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Reid Merryman, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Gottfried von Keudell, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Reid W Merryman, MD
Recruiting
Icahn School of Medicine at Mount Sinai Hospital
New York, New York, United States
Joshua Brody, MD
Recruiting
University of Rochester Medical Center
Rochester, New York, United States
Recruiting
the Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Sumana Devata, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Epcoritamab →Rituximab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Jun 2023
Primary completion: 29 Feb 2028
Completion: 28 Feb 2030
Last update posted: 22 May 2026
Registered enrollment: 100
Registry id: NCT05783609

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.